16 / 21
Cystenieren
14
1.
Buiting C, Njoo K.
Richtlijn informatie uitwisseling tussen Huisarts en Specialist bij verwijzing (HASP) .2008. Nederlands
Huisartsen Genootschap.
2.
Büscher R, Büscher AK, Weber S, Mohr J, Hegen B, Verster U, et al. Clinical manifestations of autosomal recessive polycystic kidney
disease (ARPKD): kidney-related and non-kidney-related phenotypes. Pediatr Nephrol 2014;29:1915-1925.
3.
Chapman AB, Devuyst O, Eckardt K, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD):
executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015
Jul;88(1):17-27.
4.
Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 2013 Feb;9(1):2-11.
5.
Eijssens EC. Rapport ’Spierziekten als zeldzame ziekten in de huisartsenpraktijk’. Amsterdam 2006.
6.
Gansevoort RT, Arici M, Benzin T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal
dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTAWorking Groups on Inherited Kidney
Disorders and European Renal Best Practice. Nephrol Dial Transplant 2016;0:1-12.
7.
Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, et al. Consensus expert
recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international
conference. J. Pediatr 2014 September; 165(3):611-617.
8.
Hendriks SA.
Generieke zorgthema Huisartsgeneeskundige zorg .VSOP. Soest. 2014.
9.
Harris PC, Torres VE. Polycystic Kidney Disease, Autosomal Dominant. In: Pagon RA, AdamMP, Ardinger HH, et al., editors. Seattle
(WA): University of Washington, Seattle; 1993-2016.
10. Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease. Curr Opin Pediatr 2015 Apr;27(2):186-92.
11. Niaudet P. Autosomal recessive polycystic kidney disease in children. Beschikbaar op
www.uptodate.com .Geraadpleegd op 27
februari 2016.
12. Ong ACM, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical
management. Lancet 2015;385:1993-2002.
13. Peters DJM, Losekoot M, De Die-Smulders CEM, Stevens-Baldewijns M, Breuning MH. Van gen naar ziekte; PKHD1 en recessief
erfelijke cystenieren. Ned Tijdschr Geneeskd 2005 Februari; 149(9).
14. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, Collart F, Finne P, et al. Analysis of data from the ERA-EDTA
Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy
in autosomal dominant polycystic kidney disease. Kidney International 2014;86:1244-1252.
15. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant
polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry. Nephrol
Dial Transplant 2014;29:iv15-iv25.
16. Torres V, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369: 1287-301.
17. Vajda I.
Visiedocument Concentratie en organisatie van zorg bij zeldzame aandoeningen .VSOP. Soest. 2015.
18. Wetenschap vertalen naar beleid om de ADPKD-zorg in Europa te verbeteren. Een rapport van het European ADPKD Forum.
Online beschikbaar op:
www.nvn.nl/files/nvn_nl/EAF_Report_2015b_NL.pdf .19. Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the
European Union. Nephrol Dial Transplant 2016 Jun 19;pii: gfw240.
20. Zittema D, BoertienWE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE et al. Vasopressin, copeptin, and renal concentrating
capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012
Jun;7(6):906-13.
Literatuurlijst